The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction

Franck F. Rahaghi, Robert A. Sandhaus, Charlie Strange, Douglas Kyle Hogarth, Edward Eden, James M. Stocks, Michael Joseph Krowka, James K. Stoller

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Introduction: Alpha-1 antitrypsin deficiency (AATD) is a genetic disease that may be manifested by chronic obstructive pulmonary disease. Despite professional society guidelines that recommend broad testing of at-risk individuals, fewer than 10 of affected individuals have been identified. The goals of this study were to estimate the frequency of abnormal AAT genotypes among patients found to have fixed airflow obstruction and to assess the feasibility of having Pulmonary Function Laboratory personnel administer the study. Methods: Nineteen medical centers in the United States participated in the study. Eligible patients (> GOLD II, FEV1/FVC ratio < 0.7, with post-bronchodilator FEV1<80% predicted) were offered testing for AATD by the Pulmonary Function Laboratory personnel at the time of pulmonary function testing. Results: A total of 3,457 patients were tested, of whom 3152 were eligible. Deficient patients (ZZ, SZ) constituted 0.63% of subjects, while 10.88% were carriers (MS, MZ). Neither demographic (except African-American race) nor post-bronchodilator pulmonary function variables (FEV1, FVC, FEV1/FVC ratio, TLC, and FEV1/FVC) allowed us to predict AAT heterozygote or deficiency status. Conclusions: The prevalence of AATD among patients undergoing pulmonary function tests with fixed airflow obstruction was 0.63%. Pulmonary Function Laboratory personnel effectively conducted the study.

Original languageEnglish (US)
Pages (from-to)352-358
Number of pages7
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume9
Issue number4
DOIs
StatePublished - Aug 2012

Fingerprint

alpha 1-Antitrypsin Deficiency
Laboratory Personnel
Lung
Bronchodilator Agents
Inborn Genetic Diseases
Respiratory Function Tests
Heterozygote
African Americans
Chronic Obstructive Pulmonary Disease
Genotype
Demography
Autosomal Recessive alpha-1-Antitrypsin Deficiency
Guidelines

Keywords

  • Alpha 1-Antitrypsin Deficiency
  • Chronic Obstructive Pulmonary Disease
  • Pulmonary Function Test
  • Respiratory Care
  • Spirometry

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Rahaghi, F. F., Sandhaus, R. A., Strange, C., Hogarth, D. K., Eden, E., Stocks, J. M., ... Stoller, J. K. (2012). The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. COPD: Journal of Chronic Obstructive Pulmonary Disease, 9(4), 352-358. https://doi.org/10.3109/15412555.2012.669433

The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. / Rahaghi, Franck F.; Sandhaus, Robert A.; Strange, Charlie; Hogarth, Douglas Kyle; Eden, Edward; Stocks, James M.; Krowka, Michael Joseph; Stoller, James K.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 9, No. 4, 08.2012, p. 352-358.

Research output: Contribution to journalArticle

Rahaghi, Franck F. ; Sandhaus, Robert A. ; Strange, Charlie ; Hogarth, Douglas Kyle ; Eden, Edward ; Stocks, James M. ; Krowka, Michael Joseph ; Stoller, James K. / The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. In: COPD: Journal of Chronic Obstructive Pulmonary Disease. 2012 ; Vol. 9, No. 4. pp. 352-358.
@article{90382d7db93f47b59d2fe8a3a67df5e5,
title = "The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction",
abstract = "Introduction: Alpha-1 antitrypsin deficiency (AATD) is a genetic disease that may be manifested by chronic obstructive pulmonary disease. Despite professional society guidelines that recommend broad testing of at-risk individuals, fewer than 10 of affected individuals have been identified. The goals of this study were to estimate the frequency of abnormal AAT genotypes among patients found to have fixed airflow obstruction and to assess the feasibility of having Pulmonary Function Laboratory personnel administer the study. Methods: Nineteen medical centers in the United States participated in the study. Eligible patients (> GOLD II, FEV1/FVC ratio < 0.7, with post-bronchodilator FEV1<80{\%} predicted) were offered testing for AATD by the Pulmonary Function Laboratory personnel at the time of pulmonary function testing. Results: A total of 3,457 patients were tested, of whom 3152 were eligible. Deficient patients (ZZ, SZ) constituted 0.63{\%} of subjects, while 10.88{\%} were carriers (MS, MZ). Neither demographic (except African-American race) nor post-bronchodilator pulmonary function variables (FEV1, FVC, FEV1/FVC ratio, TLC, and FEV1/FVC) allowed us to predict AAT heterozygote or deficiency status. Conclusions: The prevalence of AATD among patients undergoing pulmonary function tests with fixed airflow obstruction was 0.63{\%}. Pulmonary Function Laboratory personnel effectively conducted the study.",
keywords = "Alpha 1-Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease, Pulmonary Function Test, Respiratory Care, Spirometry",
author = "Rahaghi, {Franck F.} and Sandhaus, {Robert A.} and Charlie Strange and Hogarth, {Douglas Kyle} and Edward Eden and Stocks, {James M.} and Krowka, {Michael Joseph} and Stoller, {James K.}",
year = "2012",
month = "8",
doi = "10.3109/15412555.2012.669433",
language = "English (US)",
volume = "9",
pages = "352--358",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction

AU - Rahaghi, Franck F.

AU - Sandhaus, Robert A.

AU - Strange, Charlie

AU - Hogarth, Douglas Kyle

AU - Eden, Edward

AU - Stocks, James M.

AU - Krowka, Michael Joseph

AU - Stoller, James K.

PY - 2012/8

Y1 - 2012/8

N2 - Introduction: Alpha-1 antitrypsin deficiency (AATD) is a genetic disease that may be manifested by chronic obstructive pulmonary disease. Despite professional society guidelines that recommend broad testing of at-risk individuals, fewer than 10 of affected individuals have been identified. The goals of this study were to estimate the frequency of abnormal AAT genotypes among patients found to have fixed airflow obstruction and to assess the feasibility of having Pulmonary Function Laboratory personnel administer the study. Methods: Nineteen medical centers in the United States participated in the study. Eligible patients (> GOLD II, FEV1/FVC ratio < 0.7, with post-bronchodilator FEV1<80% predicted) were offered testing for AATD by the Pulmonary Function Laboratory personnel at the time of pulmonary function testing. Results: A total of 3,457 patients were tested, of whom 3152 were eligible. Deficient patients (ZZ, SZ) constituted 0.63% of subjects, while 10.88% were carriers (MS, MZ). Neither demographic (except African-American race) nor post-bronchodilator pulmonary function variables (FEV1, FVC, FEV1/FVC ratio, TLC, and FEV1/FVC) allowed us to predict AAT heterozygote or deficiency status. Conclusions: The prevalence of AATD among patients undergoing pulmonary function tests with fixed airflow obstruction was 0.63%. Pulmonary Function Laboratory personnel effectively conducted the study.

AB - Introduction: Alpha-1 antitrypsin deficiency (AATD) is a genetic disease that may be manifested by chronic obstructive pulmonary disease. Despite professional society guidelines that recommend broad testing of at-risk individuals, fewer than 10 of affected individuals have been identified. The goals of this study were to estimate the frequency of abnormal AAT genotypes among patients found to have fixed airflow obstruction and to assess the feasibility of having Pulmonary Function Laboratory personnel administer the study. Methods: Nineteen medical centers in the United States participated in the study. Eligible patients (> GOLD II, FEV1/FVC ratio < 0.7, with post-bronchodilator FEV1<80% predicted) were offered testing for AATD by the Pulmonary Function Laboratory personnel at the time of pulmonary function testing. Results: A total of 3,457 patients were tested, of whom 3152 were eligible. Deficient patients (ZZ, SZ) constituted 0.63% of subjects, while 10.88% were carriers (MS, MZ). Neither demographic (except African-American race) nor post-bronchodilator pulmonary function variables (FEV1, FVC, FEV1/FVC ratio, TLC, and FEV1/FVC) allowed us to predict AAT heterozygote or deficiency status. Conclusions: The prevalence of AATD among patients undergoing pulmonary function tests with fixed airflow obstruction was 0.63%. Pulmonary Function Laboratory personnel effectively conducted the study.

KW - Alpha 1-Antitrypsin Deficiency

KW - Chronic Obstructive Pulmonary Disease

KW - Pulmonary Function Test

KW - Respiratory Care

KW - Spirometry

UR - http://www.scopus.com/inward/record.url?scp=84865194902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865194902&partnerID=8YFLogxK

U2 - 10.3109/15412555.2012.669433

DO - 10.3109/15412555.2012.669433

M3 - Article

C2 - 22506682

AN - SCOPUS:84865194902

VL - 9

SP - 352

EP - 358

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 4

ER -